Highest-materiality recent filing
Lipella Pharmaceuticals files Chapter 11, sells substantially all assets to XRAIY LLC
Filed Chapter 11 on March 30, 2026 in Western District of Pennsylvania.
Lipella Pharmaceuticals files Chapter 11 bankruptcy, plans 363 sale process
Filed voluntary Chapter 11 petition in Western District of Pennsylvania on March 30, 2026.
Lipella board member Lori A. Birder resigns effective February 3, 2026
Lori A. Birder resigned from Lipella Pharmaceuticals' Board of Directors, effective immediately on February 3, 2026.
Director Naoki Yoshimura to retire from Lipella board effective Dec 31, 2025
Naoki Yoshimura notified Lipella of his intention to retire from the Board of Directors, effective December 31, 2025.
Lipella Pharmaceuticals CMO and Board Member Michael Chancellor to retire effective Dec 4, 2025
Dr. Michael Chancellor notified intention to retire as Chief Medical Officer and Board member.
All 27 patients completed 4-week treatment; no serious adverse events reported.
Lipella Pharmaceuticals Delisted from Nasdaq, Plans to Relist on National Exchange
Delisted from Nasdaq effective June 19, 2025 due to non-compliance with Listing Rules 5100, 5635, and 5640 regarding private placement transactions.
Lipella Pharmaceuticals receives Nasdaq delisting; stock moves to OTC Markets
Nasdaq Hearings Panel determined to delist Lipella common stock effective June 20, 2025; trading suspended.
Lipella sets 2025 annual meeting for July 21; record date June 18
2025 annual meeting scheduled for July 21, 2025; record date for voting is June 18, 2025.
Lipella receives Nasdaq deficiency notice for preferred stock issuance; faces potential delisting
Nasdaq notified Lipella that its Series C Preferred Stock and Warrant issuances violated Listing Rules 5635(d) and 5640 (shareholder approval and voting rights).
Lipella presents positive Phase 2a data for LP-310; 0.50mg dose shows stat-sig efficacy in OLP
Statistically significant improvements at 0.50mg dose: IGA from 3.42 to 1.71 (p=0.007), REU from 26.91 to 11.88 (p=0.003).
Lipella Pharmaceuticals regains Nasdaq equity compliance after $5.9M placement
Final closing of Series B convertible preferred stock offering on March 12, 2025; net proceeds ~$5.9M.
Lipella increases designated Series C preferred shares from 1,050,000 to 1,260,000
Filed Certificate of Amendment on April 8, 2025, increasing Series C Voting Convertible Preferred Stock designation from 1,050,000 to 1,260,000 shares.
Lipella Pharma enters $2.64M ATM equity facility with H.C. Wainwright
ATM agreement for up to $2,641,881 of common stock at market prices.
Lipella completes final close of Series B offering ($88.5K) and launches March warrant offering
Final close sold 885 shares of Series B preferred at $100/share for $88,500 gross; net proceeds $73,455.
Lipella raises $726k in fourth closing of Series B preferred offering at $2.51 conversion
Gross proceeds of $726,000 from sale of 7,260 Series B shares convertible into 289,241 common shares at $2.51/share.
Lipella raises $3.79M in third closing of Series B convertible preferred offering
Sold 37,880 Series B convertible preferred shares at $100 each; gross proceeds $3.788M, net $3.124M after fees.
Lipella Pharmaceuticals amends placement agent agreement with Spartan Capital Securities
Second Amendment removes at-the-market facility restrictions and modifies tail provision to require 10% fee on investments from accredited retail investors within one year of termination.
FDA approved Expanded Access Program for LP-310 (oral rinse for OLP) on Feb 6, 2025.
Nasdaq grants Lipella continued listing with conditions; compliance deadline April 14, 2025
Received Nasdaq Hearings Panel decision on Jan 10, 2025 granting continued listing subject to interim milestones.
Lipella raises $368K in second closing of Series B preferred offering; CEO gets voting proxy
Second closing issued 3,680 shares of Series B non-voting convertible preferred at $100/share, convertible into 117,948 common shares at $3.12/share.
Lipella Pharmaceuticals closes $2.23M initial tranche of Series B preferred offering
Initial closing of $2.23M on Dec 23, 2024: 22,295 Series B shares sold at $100 each.
Lipella special meeting cancelled due to lack of quorum; no action taken
Reconvened special meeting on Dec 27, 2024, found no quorum present.
Lipella Pharma special meeting adjourned due to lack of quorum; reconvenes Dec 27
Special meeting on Dec 20, 2024 lacked a quorum; adjourned to Dec 27, 2024 at 2:00 p.m. ET.
Lipella Pharmaceuticals enters agreement for up to $6M Series B convertible preferred offering
Offering of up to $6,000,000 in Series B non-voting convertible preferred stock; underwritten by Spartan Capital Securities.
Lipella Pharmaceuticals special meeting adjourned due to lack of quorum; reconvenes Dec 20
Lipella held special meeting Dec 6, 2024; no quorum present; meeting adjourned.
Lipella Pharmaceuticals effects 1-for-8 reverse stock split
Reverse split effective Nov 7, 2024; every 8 shares converted to 1 share.
Lipella announces 1-for-8 reverse split effective Nov 7 to meet Nasdaq bid price
Reverse stock split ratio of 1-for-8; effective 5:00 p.m. ET on November 7, 2024.
Lipella receives Nasdaq delisting notice for equity deficiency; hearing set for Dec 12
Nasdaq notified Lipella of delisting for stockholders' equity of $1.7M, below $2.5M minimum.
Lipella shareholders approve reverse stock split authorization at annual meeting
All seven director nominees elected (including CEO Jonathan Kaufman); broker non-votes of 1,703,278.
Lipella receives Nasdaq delisting notice; equity $1.7M vs $2.5M minimum
Nasdaq notified Lipella on Aug 21, 2024 of non-compliance with $2.5M minimum stockholders' equity requirement.
Lipella sets 2024 annual meeting for Sept 10; record date Aug 1
Annual meeting moved to Sept 10, 2024, more than 30 days after last year's Nov 21 meeting.
Total offering of 2,066,000 equity units (399K shares + 1,667K pre-funded warrants) at $0.62 per unit.
Lipella receives Nasdaq bid price deficiency notice; 180 days to cure
Nasdaq letter dated April 17, 2024, notes LIPO common stock closing bid price below $1.00 for 30 consecutive business days.
Lipella eliminates Series A Preferred Stock designation after all shares converted to common
Filed Series A Elimination Certificate with Delaware Secretary of State on April 11, 2024.
CEO and CMO each purchase $100k of Lipella common stock at $0.6901/share
CEO Jonathan Kaufman bought 144,906 shares for $100,000 at $0.6901/share on March 12, 2024.
Lipella believes it meets Nasdaq minimum equity rule after $2M private placement
Private placement closed Oct 25, 2023; gross proceeds $2.0M, net ~$1.7M.
Lipella receives Nasdaq deficiency notice for potential minimum equity violation
Received Nasdaq notice on Nov 21, 2023, for failure to maintain minimum $2.5M stockholders' equity as of Sep 30, 2023.
Lipella shareholders elect all 7 directors, approve share plan increase, ratify auditor
Seven director nominees elected with ~2.22M to ~2.24M votes for each; 184,927 broker non-votes.
Lipella raises $2M via private placement of pre-funded warrants and warrants
Gross proceeds ~$2M from sale of 1,315,790 pre-funded warrants (exercise $0.001) and 1,315,790 warrants (exercise $1.40) at $1.519/unit.
Lipella presents Phase 2a results for LP-10 at H.C. Wainwright conference
Presented at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11, 2023.
Lipella raises CEO and CMO salaries by $50k each
CEO Jonathan Kaufman annual base salary increased by $50,000 to $233,300 effective August 4, 2023.
Lipella Pharmaceuticals signs new lease for 3,275 sq ft office/manufacturing space
Lease with Bridgeway Development for ~3,275 sq ft at 7800 Susquehanna St, Pittsburgh, PA.
Lipella appoints Dr. Lori Birder to Board of Directors, effective June 17, 2023
Dr. Birder appointed to the Board effective June 17, 2023, to serve until next annual meeting of stockholders.
Lipella Pharmaceuticals director David Battleman resigns effective June 17, 2023
Dr. David Battleman notified the Board on May 30, 2023 of his resignation as director.
Lipella Pharma Q1 net loss $1.1M; cash $4.0M; Phase 2a LP-10 positive
Net loss of ~$1.1M for Q1 2023; cash, equivalents, and marketable securities ~$4.0M as of March 31, 2023.
Completed Phase 2a trial of LP-10 for hemorrhagic cystitis; top-line results showed no serious adverse events and reduced symptoms.
Lipella Pharmaceuticals appoints Daniel Cohen to Board and Audit Committee
Board appointed Daniel Cohen as director on March 21, 2023, expanding board to seven members.
Lipella amends 8-K to correct investor presentation; no new business details
Amendment corrects earlier 8-K that mistakenly included an earlier version of the investor presentation.
Lipella reports positive Phase 2a results for LP-10 in hemorrhagic cystitis
All 13 subjects tolerated LP-10 without product-related serious adverse events.
Effective June 17, 2023, the board of directors (the “Board”) of Lipella Pharmaceuticals Inc., a Delaware corporation (the “Company”), pursuant to its powers under the Company’s second amended and restated by-laws, appointed Dr. Lori Birder as a member of the Board.
On May 30, 2023, Dr. David Battleman informed the board of directors, or the Board, of Lipella Pharmaceuticals Inc. (the “Company”) that he will resign from the Board, effective June 17, 2023.
On March 21, 2023, the board of directors (the “Board”) of Lipella Pharmaceuticals Inc., a Delaware corporation (the “Company”), pursuant to its powers under the Company’s second amended and restated by-laws, appointed Daniel Cohen as a member of the Board, thereby increasing the Board membership count to seven (7).
Max materiality 1.00 · Median 0.60 · Most common event other_material